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Abstract
Objective: Peripheral arterial disease is one of the macrovascular complications of type 2 diabetes mellitus. This study
addresses femoral artery regulation in a prediabetic model of obese Zucker rats (OZR) by examining cross-talk between
endothelial and neural factors.
Methods and Results: Arterial preparations from lean (LZR) and OZR were subjected to electrical field stimulation (EFS) on
basal tone. Nitric oxide synthase (NOS) and cyclooxygenase (COX) isoform expression patterns were determined by
immunohistochemical labelling and Western blotting. Results indicate significantly reduced noradrenergic contractions in
preparations from OZR compared with those of LZR. Functional inhibition of endothelial NOS (eNOS) indicated a
predominant role of this isoform in LZR and its modified activity in OZR. Neural (nNOS) and inducible NOS (iNOS) were
activated and their expression was higher in femoral arteries from OZR. Neurotransmission modulated by large-
conductance Ca2+-activated (BKCa) or voltage-dependent (KV) K
+ channels did not seem compromised in the obese animals.
Endothelial COX-1 and COX-2 were expressed in LZR and an additional adventitial location of COX-2 was also observed in
OZR, explaining the higher COX-2 protein levels detected in this group. Prostanoids derived from both isoforms helped
maintain vasoconstriction in LZR while in OZR only COX-2 was active. Superoxide anion inhibition reduced contractions in
endothelium-intact arteries from OZR.
Conclusions: Endothelial dysfunction led to reduced neurogenic vasoconstriction in femoral arteries from OZR. In a setting
of obesity, NO-dependent nNOS and iNOS dilation activity could be an alternative mechanism to offset COX-2- and reactive
oxygen species-mediated vasoconstriction, along with impaired endothelial NO relaxation.
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Introduction
Peripheral arterial disease (PAD), a clinical manifestation of
atherosclerosis, is an independent risk factor of mortality and
morbidity in patients with cardiovascular diseases. Among the
complications of PAD, foot ulcers and gangrene may determine a
need for lower extremity amputation, with the consequent loss of
mobility for the patient. Patients with diabetes mellitus (DM) show
a high prevalence of PAD and DM is today the leading cause of
nontraumatic lower-limb amputation in developed countries [1].
The significant role played by factors such as obesity,
hyperglycemia, hyperlipidemia, inflammation, and oxidative stress
in the progression of diabetic complications has been well
established [2,3].
Several lines of evidence suggest that endothelial dysfunction
could be a major contributor to both macro- and microangiopathy
in DM patients and in animal models of diabetes [4,5].
Deficiencies in nitric oxide (NO), endothelium-derived hyperpo-
larizing factor and prostacyclin will affect the balance between
vasodilatation and vasoconstriction. The upregulated release of
endothelium-derived contractile factors, such as prostanoids
derived from cyclooxygenase (COX) [6], the production of
vasoconstrictor peptides, such as endothelin [7] or of radical
oxygen species (ROS) [8] are also hallmarks of endothelial
dysfunction.
The obese Zucker rat (OZR), genetic model of obesity-related
insulin resistance [9] used in this study lacks functional leptin
receptors and features the characteristics obesity, hyperglycemia,
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hyperinsulinemia and hyperlipidemia. This model therefore
closely mimics the clinical situation of a prediabetes state, in
which there is an increased risk of chronic limb ischemia. As
controls, we subjected lean Zucker rats (LZR) to the same
experimental protocol.
According to prior findings for the penile and coronary arteries
of OZR, this model shows vascular remodeling and endothelial
dysfunction along with increased oxidative stress and the reduced
bioavailability of endothelial vasodilators, such as NO and
prostacyclin [10–14].
The aim of this study was to examine the OZR model to assess
the possibility of impaired excitatory neurotransmission in the
femoral artery, as the most common anatomic location of PAD.
Also examined were the endothelial and neural components of the
femoral artery’s neurogenic response and their responsible
mechanisms.
Methods
Animal model
The investigation conformed to the European Union Guidelines
for the Care (European Union Directive (2010/63/EU) and the
Use of Laboratory Animals and all the experimental protocols
were approved by the Institutional Animal Care and Use
Committee of Madrid Complutense University.
Male LZR and OZR were purchased from Charles River
Laboratories (Barcelona, Spain) at 8–10 weeks of age. Animals
were housed at the Pharmacy School animal care facility,
maintained under standard rat room conditions and fed on
standard rat chow and tap water ad libitum, until they were used
for study, at 17–18 weeks age.
Rats were sacrificed by cervical dislocation and exsanguination.
The femoral arteries from LZR and OZR were removed, carefully
cleaned and cut into 2 mm segments.
Measurement of isometric force
Femoral artery segments were mounted isometrically in a wire
microvascular myograph system (DMT, Aarhus, Denmark) using
two 40 mm tungsten wires, for measuring generated force. The
chambers were kept at 37uC and bubbled continuously with 95%
O225% CO2 in physiological saline solution (PSS) to keep the pH
at 7.4. The composition of PSS (mM) was: NaCl 119, KCl 4.7,
CaCl2 1.5, MgSO4 1.2, NaHCO3 25, glucose 11, KH2PO4 1.2
and ethylenediaminetetraaceticacid (EDTA) 0.027.
The preparations were allowed to equilibrate for about 30 min
in PSS and washed with (37uC) PSS at 15 min intervals. After this
equilibration period, each ring was stretched at 1 min intervals to
determine the relationship between passive wall tension and
internal circumference (L). We also calculated the internal
circumference, L100, corresponding to a transmural pressure of
100 mmHg in a relaxed vessel. Subsequently, the internal
circumference of the vessels was set at L1, where L1 = 0.96L100
since force development is close to maximal at this internal
circumference. Isometric tension was recorded and displayed using
a Powerlab data system supplied with Chart v5.5 (AD Instruments,
Hastings, U.K.). At the beginning of each experiment the
preparations were stimulated once with a potassium-enriched
solution (K-PSS) to check the contractile ability of the arteries. To
prepare K-PSS, the NaCl in PSS was replaced with KCl on an
equimolar basis.
To study the role of endothelium, the luminal surface was gently
rubbed with a human hair, and successful removal of endothelium
was confirmed by the inability of acetylcholine (1–10 microM) to
relax segments precontracted with serotonin (5-HT, 0.3 microM).
Electrical field stimulation (EFS) was performed using two
262 mm platinum electrodes (DMT, Aarhus, Denmark) secured
in plastic mounting heads on either side of the preparations,
approximately 1 mm from the vessel wall. The electrodes were
connected to an electrical stimulator CS-20 (Cibertec, Barcelona,
Spain).
To obtain reproducible contractions to EFS, neuronal nor-
adrenalin re-uptake and b-adrenoceptors were blocked by
incubating the arteries for 30 min before to stimulation with,
cocaine (3 microM) and propranolol (3 microM) respectively. Two
consecutive reproducible frequency-response curves (0.5–32 Hz,
20 s trains, 0.2 ms pulses, 65 mA) were obtained in preparations
Figure 1. Decreased neurogenic vasoconstrictor response from obese Zucker rat femoral artery. Representative tracings showing the
contractile effect evoked by electrical field stimulation (EFS) in femoral artery from LZR and OZR. ACh, acetylcholine (1 microM); 5-HT, serotonin (0.3
microM); W, washout. Vertical bar indicates increase in force (mN), and horizontal bar indicates time (min).
doi:10.1371/journal.pone.0106372.g001
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under resting tension [15]. To study the mechanisms underlying
EFS- induced contractile responses, different antagonists, inhibi-
tors and blockers were added to the organ bath 30 min before
conducting the second frequency- response curves.
In preliminary experiments, EFS was applied in the presence of
a blocker of neuronal voltage-gated Na+ channels, tetrodotoxin (1
microM), to assess the neurogenic character of the EFS- elicited
responses.
To study the nature of EFS- induced contractile responses the
arterial segments were treated with the adrenergic neurotransmis-
sion blocker, guanethidine (10 microM), the alpha-adrenoceptor
antagonist, phentolamine (10 microM), the selective alpha1-
adrenoceptor antagonist, prazosin (1 microM). To evaluate the
role of NO, preparations were incubated with Nomega-nitro-L-
arginine (L-NOARG, 100 microM) to not selectively inhibit NO
synthase (NOS) or with Nomega-propyl-L-arginine (3 microM) to
inhibit neuronal NOS (nNOS) or with 1400 W (10 microM) to
inhibit inducible NOS (iNOS). The type of potassium channel was
determined using the non-selective Ca2+-activated K+ (KCa)
channel blocker, tetraethylammonium (TEA, 1 mM); specific
blockers such as the blockers of large- (BKCa), iberiotoxin (0.1
microM); intermediate- (IKCa), TRAM-34 (3 microM); or small-
conductance KCa channels (SKCa) apamin (0.3 microM); of
voltage-dependent K+ channels (KV), 4-aminopyridine (100
microM); of ATP-dependent K+ channels (KATP), glibenclamide
(1 microM); or inward rectifier K+ channels (Kir), barium chloride
(BaCl2, 30 microM). Ouabain (10 microM), a Na
+-K+ ATPase
pump inhibitor was also used. Contribution of prostanoids to EFS-
induced responses was investigated by using the non-selective
cyclooxygenase (COX) inhibitor, indomethacin (1 microM) and
selective COX-1 and COX-2 inhibitors, SC-560 (1 microM) and
NS-398 (1 microM) respectively. Involvement of reactive oxygen
Figure 2. Role of the endothelium in adrenergic responses induced by EFS. Neurogenic contractions were obtained in the absence and
presence of guanethidine (10 microM), phentolamine (10 microM) and prazosin (1 microM) in femoral artery from LZR (A) and OZR (B). Data are
means 6 S.E.M. for values obtained in 7–9 animals. (C) Neurogenic contractions were obtained in femoral artery with endothelium (E+) and without
endothelium (E2) from LZR and OZR. Data are means 6 S.E.M. for values obtained in 15–20 animals. *P,0.05; **P,0.01; ***P,0.001 significance
compared to endothelium-intact segments; # P,0.05 obese versus lean.
doi:10.1371/journal.pone.0106372.g002
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species, NADP(H)-oxidase and endothelin receptors in the
contractile responses was analysed by adding to the organ bath
superoxide dismutase (SOD, 150 U/mL) or apocynin (100
microM) and bosentan (10 microM), respectively.
Immunohistochemistry
Femoral artery segments were fixed by immersing in 4%
paraformaldehyde prepared in 0.1 M sodium phosphate buffer
(PB), pH 7.4 at 4uC for 3–4 h, and then placed in a cryoprotective
phosphate buffer solution containing 30% sucrose for 24 h at 4uC.
The tissue was embedded and frozen in OCT compound (Tissue-
Tek. Sakura Finetek, Europe B.V.), and stored at 280uC.
Transversal sections 5 microm thick were obtained by means of
a cryostat.
For immunohistochemistry using avidin–biotin–peroxidase
complex procedures [16], the tissue sections were immersed in a
mixture of 1% H2O2 and 90% methanol in distilled water and
then washed in PB (3610 min). Specimens were preincubated for
3 h in 10% normal goat serum in PB containing 0.3% Triton X-
100 to detect endothelial, neuronal and inducible NOS, and in 5%
bovine serum albumin and 10% normal goat serum in PB
containing 0.3% triton X-100 to detect COX-1 and COX-2.
Next, the sections were treated with rabbit anti-eNOS antibody
(Chemicon International Inc.) diluted 1:500 in PB, rabbit anti-
nNOS (Chemicon International Inc.) diluted 1:1000 in PB, rabbit
anti-iNOS (Santa Cruz Biotechnology Inc.) diluted 1:50 in PB and
rabbit anti-COX-1 and COX-2 (Santa Cruz Biotechnology Inc)
diluted 1:50 in PB. Sections were then incubated for 2 h at room
temperature with biotinylated anti-rabbit serum raised in goat
(Chemicon International Inc., Phillipsburg, NJ, USA) diluted
1:400. Once treated with the avidin–biotin complex (ABC, Vector)
diluted 1:100 for 90 min at room temperature, the resultant
immunocomplex was visualized using 0.05% 3,39-diaminobenzi-
dine and 0.001% H2O2 in PB. No immunoreactivity could be
detected in sections incubated in the absence of the primary
antisera.
Western blots
Femoral artery segments were homogenized (MagNA Lyser,
Roche, IN, USA) in radioimmunoprecipitation assay (RIPA)
buffer containing protease inhibitor cocktail tablets at the
concentration supplied by the manufacturer (Complete Mini,
Roche, IN, USA). Protein contents were determined using the
BCA (bicinchoninic acid) Protein Assay Kit (Thermo Scientific
Pierce, Madison, WI, USA) and equal amounts of whole vessel
homogenates were electrophoresed on 7.5% SDS-polyacrylamide
and transferred to polyvinylidene difluoride membranes. After
blocking, the membranes were incubated overnight (4uC) with
primary antibodies against eNOS (Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA), iNOS (BD Transduction Laboratories,
Madrid, Spain), nNOS (BD Transduction Laboratories, Madrid,
Spain), COX-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) and COX-2 (Santa Cruz Biotechnology Inc, Santa Cruz,
CA, USA). As positive controls were used cell lysate from mouse
macrophages stimulated with 10 ng/mL interferon gamma
(IFNgamma) and 1 microg/mL lipopolysaccharide (LPS), for
iNOS (BD Transduction Laboratories, Madrid, Spain); rat
cerebrum lysate for nNOS (BD Transduction Laboratories,
Madrid, Spain); cell lysates from human umbilical vein endothelial
cells (HUVEC) for eNOS and COX-1; and cell lysate from
HUVEC treated with 1 microg/mL LPS for COX-2. As internal
control of the amount of protein, beta-actin (Sigma–Aldrich, St.
Louis, MO, USA) was used. After incubation with secondary
antirabbit or anti-mouse antibodies as appropriate, antibody
binding was assessed by enhanced chemiluminescence (Thermo
Scientific Pierce ECL Western Blotting Substrate, Madison, WI,
USA). Blots were digitalized using a Gelprinter Plus (TDI, Madrid,
Spain) and the densities of spots assessed using Image Gauge 4.0
software (Fujifilm Science Lab, Madrid, Spain).
Drugs and solutions
The following drugs were used: acetylcholine, 4-aminopyridine,
apamin, 49-hydroxy-39-methoxyacetophenone (apocynin), barium
chloride, cocaine, glibenclamide, guanethidine, 5-HT, iberiotoxin,
indomethacin, L-NOARG, Nomega-propyl-L-arginine, phentol-
amine, ouabain, prazosin, propranolol, SOD, tetrodotoxin, TEA
and 1-(2-Chlorophenyl) diphenylmethyl- 1H-pyrazole (TRAM-34)
(Sigma Chemical Co, St Louis, MO, USA). NS-398, SC-560 and
1400 W were purchased from Tocris Cookson (Bristol, UK).
Bosentan was a gift from F. Hoffman-La Roche Laboratories
(Basel, Switzerland).
All drugs were added in volumes not exceeding 0.3% of the
organ baths to reach the final required concentration. They were
dissolved in distilled water with the exception of indomethacin
which was prepared in ethanol (96%), glibenclamide, SC-560 and
NS-398 which required dimethylsulphoxide (10%). Preliminary
experiments revealed no effects of the solvent used on the
contractility of the preparations. Stock solutions were prepared
and stored at 220uC and fresh solutions were prepared daily.
Data calculations and statistics
The mechanical responses of the arteries were expressed as
active wall tension (N?m21). Contractions are either expressed as
tension or as percentage of contraction induced by K-PSS. Results
are expressed as means 6 S.E.M. of n rats. Statistical differences
were analyzed using one-way ANOVA or paired or unpaired
Student’s t-test when appropriate. Probability levels less than 5%
were considered significant (P,0.05). All calculations were made
using a standard software package (Prism 4.0, GraphPad San
Diego, CA).
Results
General parameters
The OZR were significantly heavier (474.364.8 g versus
370.364.7 g; P,0.001, n = 40) than LZR (both strains 17–18
weeks of age). We previously reported that at this age animals in
the obese group show mild hyperglycemia, hyperinsulinemia and
dyslipidemia with elevated total cholesterol and triglyceride levels
[11]. Normalized vessel internal lumen diameters, L1, were similar
Figure 3. Role of eNOS in contractile responses induced by EFS. Neurogenic contractions were obtained in the absence and presence of a
NOS inhibitor, L-NOARG (100 microM) in femoral artery with endothelium (E+) from LZR (A) and OZR (B) and without endothelium (E2) from LZR (C)
and OZR (D). Data are means6 S.E.M. for values obtained in 7–8 animals. *P,0.05; **P,0.01 versus L-NOARG-treated. Representative original pictures
of cross-sections of femoral artery from LZR (E) and OZR (F) showing immunoreactivity for eNOS in the endothelial cell layer (arrows). Note that
localization of eNOS immunoreaction was similar in LZR and OZR. (G) A representative immunoblotting image and relative levels assessed by
densitometry of eNOS protein expression in femoral artery from LZR and OZR are presented. Data are means 6 S.E.M. for values obtained in 6
animals.
doi:10.1371/journal.pone.0106372.g003
Neurogenic Vasoconstriction in Obese Zucker Rat
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e106372
Neurogenic Vasoconstriction in Obese Zucker Rat
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e106372
in the OZR (443.667.8 microm) and lean animals (435.3610.8
microm; n = 40). Also, reactivity to depolarization with K-PSS was
comparable in both groups of arteries (LZR, 10.660.7 N?m21;
OZR, 11.260.9 N?m21; n = 40), suggesting the unaltered
contractility of arterial smooth muscle.
Reduced neurogenic vasoconstriction in femoral arteries
from OZR
EFS-evoked frequency-dependent contractions were of a lesser
magnitude in femoral arteries isolated from OZR than LZR at all
frequencies examined (Figure 1). EFS-induced contractions were
abolished by the neuronal voltage-gated Na+ channel blocker,
tetrodotoxin (1 microM), and markedly reduced by guanethidine
(10 microM), a noradrenergic neurotransmission inhibitor, phen-
tolamine (10 microM), an alpha-adrenoceptor antagonist, and
prazosin (1 microM), a selective alpha1 -adrenoceptor antagonist
(Figure 2A and B). Similarly, alpha1-adrenergic receptor blockade
potently inhibited the contraction induced by EFS in rings devoid
of endothelium (data not shown). These results indicate that
noradrenaline is the main contributor to the neurogenic contrac-
tion, via alpha1 receptor activation.
Endothelial cell removal reduced contractions induced by EFS
compared to endothelium-intact preparations in both strains,
though to a greater extent in LZR (Figure 2C). Having ruled out
the presence of endothelial alpha1 adrenoceptors, our results
indicate that endothelial denudation has differential effects on
excitatory neurotransmission in arteries obtained from both
experimental groups (Figure 2C).
Expression and function changes induced in the NOS
isoforms involved in neurogenic vasoconstriction in OZR
In arteries with an intact endothelium, L-NOARG (100
microM) potentiated the contractile responses of the arterial rings
to sympathetic neurogenic stimulation in LZR (Figure 3A), but did
not modify EFS contractile responses in denuded segments from
the same group (Figure 3C). Conversely, in arterial segments from
the OZR group, the contraction induced by EFS was enhanced in
both intact and denuded preparations when NOS activity was
inhibited (Figure 3B and D). Immunoreactivity for eNOS in cross
sections of femoral arteries revealed no differences in the presence
and distribution of this constitutive NOS isoform in the
endothelium of femoral arteries in OZR (Figure 3F) compared
with LZR (Figure 3E). Western blotting of eNOS protein
confirmed no significant differences in the levels of expression
between the LZR and OZR groups (Figure 3G). The expression of
beta-actin was not significantly different between LZR and OZR.
The selective nNOS inhibitor, Nomega-propyl-L-arginine (3
microM), significantly enhanced vasoconstriction in endotheli-
um-free femoral arteries in OZR (Figure 4B) but did not modify
responses in LZR (Figure 4A). Arterial cross sections immunola-
belled with an antibody against nNOS revealed higher nNOS
immunoreactivity in OZR (Figure 4D) than LZR (Figure 4C). In
LZR, nNOS expression was observed only within the adventitial
perivascular nerves while in OZR this expression was also detected
in the endothelial lining of the femoral artery (Figure 4D). Western
blots supported the increased expression of nNOS in the arteries
harvested from OZR (Figure 4E).
Exposure of the denuded femoral rings to the iNOS selective
inhibitor 1400 W (10 microM) led to increased vasoconstriction
responses only in OZR, as also observed for nNOS (Figure 5A and
B). Immunoreactivity against iNOS, more intense in femoral
arteries from OZR, was observed between the smooth muscle and
adventitia layers (Figure 5C and D). Also, we detected a significant
increase in iNOS protein expression in femoral arteries from OZR
by Western blotting (Figure 5E).
These observations suggest the induction of nNOS and iNOS
activities in OZR in response to the loss of eNOS activity.
Modulation of K+ channels of neurogenic
vasoconstriction is unmodified in OZR
TEA (1 mM), a non-selective blocker of KCa channels
(Figure 6A and B), and the selective blocker of BKCa iberiotoxin
(0.1 microM) (Figure 6C and D) increased the contraction
response to EFS in femoral arteries obtained from LZR and
OZR. The extent of potentiation of adrenergic contractions
induced by these blockers was comparable between both groups.
The blocker of IKCa TRAM-34 (3 microM), or SKCa apamin (0.3
microM) had no effect on neurogenic responses in LZR and OZR
arteries (data not shown). The specific blocker of KV, 4-
amynopiridine (0.1 mM), enhanced EFS-evoked contractions in
LZR and OZR femoral arteries (Figure 6E and F). The magnitude
of this increase was similar in both experimental groups. Blockade
of KATP with glibenclamide (1 microM), and of Kir with BaCl2 (30
microM) and a Na+-K+ ATPase pump inhibitor, ouabain (10
microM) did not affect the contractions elicited by EFS in arterial
rings from either group. These results were not significantly
different to those recorded in denuded arteries (data not shown).
Collectively, these observations suggest that the condition of
obesity does not affect the modulatory role of neural vasocon-
striction of K+ channels, KCa and Kv, which are functionally
active in the femoral artery of the Zucker rat.
Expression and function changes induced in the COX
isoforms involved in neurogenic vasoconstriction in OZR
In the presence of the non-selective COX inhibitor, indometh-
acin (1 microM), a significant decrease in the contractile response
to EFS was produced in arterial segments with an intact
(Figure 7A) but not a denuded endothelium in the LZR group
(Figure 7C). In femoral arteries from OZR, indomethacin
significantly reduced adrenergic contractions both in segments
with and without an endothelium (Figure 7B and D). To assess the
specific COX isoform involved, we examined the effects of the
selective COX-1 inhibitor, SC-560 (1 microM), and the selective
COX-2 inhibitor, NS-398 (1 microM) on contractile responses to
EFS. Treatment with SC-560 reproduced the effect of indometh-
acin in segments from LZR (Figure 8A and C), but in those from
OZR, frequency-dependent responses were not inhibited, inde-
pendently of the presence of endothelium (Figure 8B and D).
Immunohistochemical staining showed the presence of the
constitutive COX-1 isoform throughout the endothelial layer of
Figure 4. Role of nNOS in contractile responses induced by EFS. Neurogenic contractions were obtained in the absence and presence of
selective neural NOS inhibitor, Nomega-propyl-L-arginine (3 microM) in femoral artery without endothelium (E2) from LZR (A) and OZR (B). Data are
means6 S.E.M. for values obtained in 7–8 animals. *P,0.05. Representative original pictures of cross-sections of femoral artery from LZR (C) and OZR
(D) showing immunoreactivity for nNOS between the muscle and adventitia layer of the femoral arteries (arrows). Note that nNOS inmunoreaction
was also localized in the endothelial cell layer of the femoral artery from OZR. (E) A representative immunoblotting image and relative levels assessed
by densitometry of nNOS protein expression in femoral artery from LZR and OZR are presented. Data are means 6 S.E.M. for values obtained in 6
animals. *P,0.05.
doi:10.1371/journal.pone.0106372.g004
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femoral arteries in both strains (Figure 8E and F). Western blotting
revealed a similar COX-1 expression pattern in segments from
LZR and OZR (Figure 8G).
Following COX-2 inhibition, EFS also gave rise to a reduced
contraction response in LZR arteries with an intact endothelium
(Figure 9A) whereas the contractile response was unaffected in
matched arterial segments denuded of endothelium (Figure 9C).
The contraction elicited by EFS in the presence of NS-398 was
significantly diminished in OZR arteries with and without
endothelium (Figure 9B and D). Femoral arterial sections labelled
with antibody against COX-2, also showed that this isoform was
primarily expressed in the arterial endothelial layer in LZR
(Figure 9E) and the endothelial and adventitial layers in OZR
(Figure 9F). Western blotting revealed augmented COX-2 protein
contents in femoral arteries from OZR (Figure 9G). These findings
seem to indicate that while the COX-1 isoform loses its functional
activity, COX-2 is upregulated in arteries from obese animals.
Other contractile factors involved in neurogenic
vasoconstriction: key role of superoxide anions in OZR
Independently of the presence of endothelium, the neurogenic
response was unaltered by prior incubation with the superoxide-
scavenging compound, SOD (150 U/mL), in segments from LZR
(Figure 10A and C). However, SOD decreased EFS-induced
contractions in endothelium-intact arteries from OZR (Fig-
ure 10B) but did not modify those produced in arteries without
endothelium (Figure 10D).
EFS-contractile response curves were unmodified by the
vascular NADP(H)-oxidase inhibitor apocynin (100 microM) in
endothelium-intact and denuded femoral arteries from both
groups (data not shown).
However, femoral arteries with or without endothelium from
LZR and OZR showed a similar contraction response to EFS in
the presence of the non-selective endothelin (ETA/B) receptor
blocker, bosentan (10 microM) (Figure 10E–H).
Discussion
The present study provides evidence of diminished neurogenic
contractions due to endothelial dysfunction in femoral arterial
preparations from OZR. In this model of obesity, the compen-
satory expression and functional involvement of nNOS and iNOS
could be a protective strategy that generates superoxide anions in
place of endothelial NO. At this stage, NO from non-eNOS could
exert a considerable inhibitory effect that overrides the functional
response of both augmented COX-2 expression coupled to
vasoconstrictor release and enhanced ROS production, thus
contributing to the reduced magnitude of neurogenic responses.
The OZR model has been well defined in terms of biochemistry
and vascular function. We reported previously that OZR exhibits
characteristics of the typical metabolic syndrome that accompanies
prediabetes or insulin resistance in humans [11]. Oltman et al.
[17] reported different rates of the development of vascular and
neural dysfunction in diabetic and obese Zucker rats and
attributed the difference to hyperglycemia, indicating that
microvascular impairment preceded the appearance of nerve
dysfunction [17]. The predominant nerve dysfunction mechanism
observed in obesity of increased vasoconstrictor responses to EFS
is driven by sympathetic nerve activation or direct adrenergic
receptor stimulation [18,19]. However, it is not clear whether
there is an etiological mechanism in patients that is nerve-specific,
rather than being simply a reflection of the neural consequences of
the physiological challenge of vascular dysfunction. In the present
study, obesity led to diminished neurogenic contractions, which
could represent a mechanism designed to preserve adequate blood
flow to the lower limbs in individuals in a prediabetic state. This
reduced reactivity to constriction was not attributable to changes
in the intrinsic contractile machinery as indicated by the similar
depolarization -induced contractions elicited by a high potassium
solution in LZR and OZR, as in the coronary arteries from this rat
model. On the contrary, in penile arteries from OZR the reduced
maximal contractile responses elicited by K-PSS probably reflect
the smaller size of arteries due to structural remodelling [10]. The
fact that guanethidine, phentolamine and prazosin greatly
diminished the vasoconstriction response to EFS in arterial
segments from both groups of rats, indicates that noradrenaline
release from periarterial adrenergic nerves mediates this response
by activating postsynaptic alpha1-adrenoceptors, as reported for
the femoral artery of Wistar rats [20]. Thus, the differences in
neurogenic contraction observed may not be attributed to release
of noradrenaline and/or adrenergic innervation differences
between LZR and OZR.
In contrast with our findings, adrenergic hyperactivity has been
observed in a setting of obesity [18,19]. However, these
experiments were performed in endothelium-denuded segments
and interactions between endothelium-derived factors and neuro-
transmitters may affect EFS responses [21].
Our observations suggest that endothelial dysfunction was
responsible for the diminished contractions observed in OZR since
both groups of animals showed a similar response when
experiments were conducted on denuded segments. Other studies
have also revealed endothelial dysfunction in penile arteries in the
same model [10,11].
It has been well established that endothelial mediators may
indirectly regulate vascular function by modulating sympathetic
neurotransmission [15,21–23]. In fact, vasoconstriction resulting
from the release of noradrenaline from sympathetic nerve
terminals induces the release of NO from the endothelium
[15,21,23].
Through immunohistochemical labelling, we localized eNOS at
the endothelium and its expression detected by Western blotting
was unmodified in our OZR. Upon nerve stimulation, NO
synthesis inhibition by L-NOARG led to enhanced vasoconstric-
tion of the intact femoral artery in both LZR and OZR. However,
we detected NOS activity in denuded femoral arteries only in
OZR. These findings point to modified eNOS activity in OZR
and the similar L-NOARG effect observed in arterial rings with
and without endothelium may be the outcome of inhibition of
other NOS isoforms. Possible factors contributting to altered
eNOS activity in OZR vessels include eNOS enzyme phosphor-
ylation or other posttranslational modifications or the increased
expression/activity of isoforms such as nNOS and iNOS. The
Figure 5. Role of iNOS in contractile responses induced by EFS. Neurogenic contractions were obtained in the absence and presence of
selective inducible NOS inhibitor, 1400 W (10 microM) in femoral artery without endothelium (E2) from LZR (A) and OZR (B). Data are means6 S.E.M.
for values obtained in 7–9 animals. *P,0.05. Representative original pictures of cross-sections of femoral artery from LZR (C) and OZR (D) showing
immunoreactivity for iNOS between the smooth muscle and adventitia layer of the femoral arteries (arrows). Note that iNOS inmunoreaction was
more intense in the femoral arteries from OZR. (E) A representative immunoblotting image and relative levels assessed by densitometry of iNOS
protein expression in femoral artery from LZR and OZR are presented. Data are means 6 S.E.M. for values obtained in 7–8 animals. *P,0.05.
doi:10.1371/journal.pone.0106372.g005
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latter is supported by observations that when NOS was blocked
denuded femoral artery rings from OZR showed enhanced
neurogenic vasoconstriction together with an increased response
to EFS by the highly selective nNOS and iNOS inhibitors.
Therefore nNOS and iNOS seems not to be activated in control
conditions. The protein expression of both isoforms determined by
immunohistochemical and biochemical procedures was higher in
the femoral arteries from OZR. Evidence from several studies
suggests that in mice genetically deficient in one of the constitutive
NOS isoforms, the remaining constitutive isoform takes on some of
the functions normally attributed to the deleted enzyme [24].
Under arteriosclerotic/inflammatory conditions accompanied by
eNOS dysfunction, nNOS serves as an alternative source of NO,
inhibiting vascular lesion formation and a rise in vascular tone
[24]. Interestingly, in our study nNOS was detected both in the
adventitial perivascular nerves and the endothelium lining in
preparations from OZR. This observation is in agreement with
earlier reports in which nNOS was detected in the neointima,
endothelial cells and macrophages in both early and advanced
Figure 6. Preserved function of K+ channels in responses induced by EFS. Neurogenic contractions were obtained in femoral artery with
endothelium (E+) in the absence and presence of TEA (1 mM), a non-selective KCa blocker from LZR (A) and OZR (B), in the absence and the presence
of the BKCa blocker, iberiotoxin (0.1 microM) from LZR (C) and OZR (D) and in the absence and presence of a KV blocker, 4-amynopiridine (100
microM) from LZR (E) and OZR (F). Data are means 6 S.E.M. for values obtained in 6–7 animals. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0106372.g006
Figure 7. Role of COX in contractile responses induced by EFS. Neurogenic contractions were obtained in the absence and presence of a
non-selective COX inhibitor, indomethacin (1 microM) in femoral artery with endothelium (E+) from LZR (A) and OZR (B), and without endothelium
(E2) from LZR (C) and OZR (D). Data are means 6 S.E.M. for values obtained in 6–7 animals. *P,0.05.
doi:10.1371/journal.pone.0106372.g007
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atherosclerotic lesions [25]. The role of nNOS expressed in these
vascular lesions remains to be determined.
In recent years, iNOS has been attributed an ever increasing
role in mechanisms of vascular dysfunction, whereby the
overproduction of NO has been linked to several pathophysiolog-
ical conditions including insulin resistance and vascular inflam-
mation [26]. Hence, in our femoral artery preparations from obese
animals, the loss of endothelial NO was partially offset by
activation of these alternative pathways, including the production
of NO derived from nNOS and iNOS, which may avoid an
increase in vascular tone.
In a previous study, we detected a dysfunctional nitrergic system
in penile arteries from insulin resistant OZR that was able to
explain enhanced noradrenergic vasoconstriction elicited by nerve
stimulation [14]. These findings suggest that obesity may
differentially impair neurogenic responses in different vascular
settings.
Endothelial dysfunction has been described as the consequence
of increased oxidative stressor production. Reactive oxygen species
(ROS), mainly superoxide anions, are highly reactive and destroy
NO, thus reducing its bioavailability and producing peroxynitrites.
One source of ROS is uncoupled eNOS. eNOS uncoupling is a
process whereby eNOS generates superoxide (O2
2) in conditions
of depleted substrate or NOS cofactor concentrations [27].
Elevated superoxide levels were detected in epineurial arterioles
and aorta in obese rats developing microvascular and neural
dysfunction [17].
Under these same conditions of insulin resistance, modified
neural NO-mediated relaxant responses due to oxidative stress
have been reported in penile arteries [14]. The present results
suggest that oxidative stress may be involved in the changes that
limit the activity of endothelial NO, due to the inhibitory effect of
SOD in femoral arteries from obese animals with an intact
endothelium but not in denuded preparations. This effect was not
observed in the femoral artery from LZR. Thus, it is likely that
endothelium- derived ROS production may explain the absence of
L-NOARG effect noted in intact femoral artery segments from
OZR.
Superoxide anions are generated by several sources including,
besides uncoupled eNOS, NADPH oxidase and COX. Since the
major source of ROS in the vasculature is vascular NADPH
oxidase [28], it could be a key enzyme linked to oxidative stress in
this pathogenic cascade. However, vascular NADPH oxidase was
ruled out indicating the uncoupling of eNOS and/or COX as
possible mechanisms responsible for the increased ROS levels
observed here in femoral arteries from OZR.
In a setting of obesity, vasodilation in response to endothelium-
derived hyperpolarization (EDH) may be impaired due to changes
in underlying potassium channel signalling mechanisms. In obese
rat saphenous artery, the role of NO was significantly impaired
and offset by the appearance of IKCa and myoendothelial gap
junctions, to maintain endothelium-dependent vasodilation [29].
The findings of our study suggest that the Na+-K+ ATPase pump,
KATP, Kir, IKCa and SKCa did not contribute to EFS-induced
contractile responses in both strains of rats. In contrast, BKCa and
KV were identified here as K
+ channels modulators of neural
regulation in LZR femoral adrenergic transmission yet were
unaffected by the conditions of obesity. As for the other
components of the vasculature, during persistent high blood
pressure, potassium channels in the plasma membrane of vascular
smooth muscle cells undergo remodelling to maintain a height-
ened vascular tone [30]. In the present study, the preserved
function of K+ channels in OZR could be explained by the lack of
hypertension in our model [10], contrasting with the mild
hypertension present in the diet-induced obesity rodent model
[31].
There is mounting evidence to support the idea that the
enhanced constrictor prostanoid production may play a key role in
the pathogenesis of vascular dysfunction associated with diabetes.
Cyclooxygenase enzymes may cause vascular hyper-contractility
by increasing the synthesis of constrictor prostanoid(s) and
excessive ROS formation [8,32,33].
In the vascular wall, both endothelial and smooth muscle cells
contain COX-1 and COX-2. However, the endothelial cells of
healthy blood vessels appear to contain much more COX-1
enzyme than surrounding smooth muscle cells [34]. Originally it
was thought that COX-2 was largely responsible for the
pathological production of prostanoids, for instance in inflamma-
tory conditions, but it is now understood that COX-2 may play
both a physiological and pathological roles [35].
The present results indicate that contractile prostanoids evoked
by EFS in arteries from LZR are in fact derived from COX-1 and
COX-2 in the endothelium, since non-selective and selective
inhibitors of both isoforms reduced EFS-responses in endothelium-
intact rings but did not alter contractions in denuded preparations.
Moreover, the presence of COX-1 and COX-2 in femoral arteries
from LZR detected by immunohistochemical staining and
Western blotting, supports the fact that prostanoid synthesis could
occur in the endothelium. Prostanoid derivative synthesis could
explain the reduction observed in neurogenic contractions when
comparing endothelial-intact with denuded femoral artery rings.
Thus, activation of both COX isoforms could be an integral part
of the endothelium-derived mechanisms that regulate local
femoral vascular function in LZR, mainly via the formation of
contractile prostanoids. This observation is consistent with the
findings of a previous study in which we noted that in penile artery
preparations from the same obese rat model, constitutive active
COX-1 and COX-2 pathways were involved in regulating
vascular tone in physiological conditions [12].
By immunostaining, COX-1 and COX-2 were also localized in
the endothelium of femoral arteries from OZR. Further, COX-2
was also expressed in adventitial cells of arteries from OZR. While
in obesity COX-1 expression remained stable, the greater
expression of COX-2 protein was detected by Western blotting.
Thus, it seems that when COX-1 enzyme is dysfunctional in
OZR, COX-2 is able to metabolize arachidonic acid into
vasoactive prostanoids [13]. The fact that the COX-2 inhibitor
NS-398 reduced EFS-responses in femoral rings with or without
endothelium from obese animals suggests that contractile prosta-
noids could also be produced from a non-endothelial source, for
instance, perivascular macrophages. Thus, in OZR, the relaxant
opposing effect of NO derived from neural and inducible sources
Figure 8. Role of COX-1 in contractile responses induced by EFS. Neurogenic contractions were obtained in the absence and presence of the
selective COX-1, SC-560 (1 microM) in femoral artery with endothelium (E+) from LZR (A) and OZR (B) and without endothelium (E2) from LZR (C) and
OZR (D). Data are means6 S.E.M. for values obtained in 6–7animals. *P,0.05 versus SC-560-treated. Representative original pictures of cross-sections
of femoral artery from LZR (E) and OZR (F) showing immunoreactivity to COX-1 in endothelial layer (arrows). Note that localization of COX-1
immunoreaction was similar in LZR and OZR. (G) A representative immunoblotting image and relative levels assessed by densitometry of COX-1
protein expression in femoral artery from LZR and OZR are presented. Data are means 6 S.E.M. for values obtained in 6 animals.
doi:10.1371/journal.pone.0106372.g008
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Figure 9. Role of COX-2 in contractile responses induced by EFS. Neurogenic contractions were obtained in the absence and presence of the
selective COX-2, NS-398 (1 microM) in femoral artery with endothelium (E+) from LZR (A) and OZR (B) and without endothelium (E2) from LZR (C) and
OZR (D). Data are means6 S.E.M. for values obtained in 6–7animals. *P,0.05 versus NS-398-treated. Representative original pictures of cross-sections
of femoral artery from LZR (E) and OZR (F) showing immunoreactivity to COX-2 in endothelial layer (arrows). Note that additional COX-2
immunostaining was also found in the adventitial layer from OZR. (G) A representative immunoblotting image and relative levels assessed by
densitometry of COX-2 protein expression in femoral artery from LZR and OZR are presented. Data are means 6 S.E.M. for values obtained in 6
animals. *P,0.05.
doi:10.1371/journal.pone.0106372.g009
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probably hinders prostanoid-induced contraction leading to an
EFS contractile response of lesser magnitude. Therefore, it is
possible that these mediators, NOS and COX derivatives, interact
with each other to maintain an appropriate basal tone. Oxidative
stress could activate COX, which in turn, would give rise to the
increased formation of vasoconstrictor prostanoids. These would
also most likely drive the enhanced formation of ROS, leading to a
vicious positive-feedback cycle of ROS production perpetuating
the endothelial dysfunction [36]. Our findings point to excess
ROS as a possible mechanism for the increased COX-2 expression
observed in obese rats [34,36].
In a prediabetic state in which compensating mechanisms
predominate, it could be that the disruption of a COX pathway
will trigger other metabolic pathways [37] contributing to other
important physiopathological alterations, such as platelet aggre-
gation or changes in the stability of atherosclerotic plaques
[37,38]. The outcome of COX-2 activity and subsequent
prostanoid signalling will therefore depend on highly dynamic
balance among these different and often conflicting signals. The
impact of the vasoconstrictor effect of prostanoid synthesis may
also increase as diabetes sets in [39].
The endothelium also produces endothelin-1 (ET-1), another
essential factor for modulating vascular responses. In a setting of
disease, this peptide has profound vasoconstrictor effects and
contributes to changes in blood flow in the diabetic vasculature
[40]. The results of the present study are inconsistent with the
findings of studies that have indicated that overweight and obesity,
independent of traditional cardiovascular risk factors, are associ-
ated with elevated ET-1- mediated vasoconstriction [41]. Howev-
er, findings in this regard have been conflicting, with reports
existing of either an increased or a normal contractile response to
ET-1 in OZR arteries [42–44]. In fact, penile arteries harvested
from the same rat model showed impaired ET-1 Ca2+ signalling
along with changes in the ET receptor profile [45]. On the
contrary, in the present study based on the lack of an effect of
bosentan on EFS-induced contractions in LZR and OZR femoral
rings, we were able to rule out ET-1 as the mediator involved in
regulating contractile neurotransmission, reinforcing the idea that
obesity does not equally affect all vascular beds.
The endothelial dysfunction observed here in femoral arteries
from OZR may be attributable to diminished endothelial NO
production leading to ROS. A compensation mechanism may
exist to preserve relaxation involving NO derived from neural and
inducible NOS to offset the EFS-evoked contraction when an
essential vasodilator is lacking. Indeed, the augmented expression
of nNOS and iNOS in OZR may serve as a protective strategy
against the overexpression and contractile effect of COX-2. The
present findings agree with the view that in most diseases there is a
prodromal period in which the body tries to defend and maintain
the organic homeostasis against an aggression (metabolic, infec-
tious, etc.). In this case, obesity may precede a state of type II
Diabetes Mellitus, the body defends itself against observed eNOS
dysfunction and overexpression of COX-2 by activating iNOS and
nNOS, as a compensatory mechanism, thus resulting in a
sympathetic vasoconstriction response would be even lower than
under control conditions. This compensatory mechanism gives a
delayed onset of the clinical period of the cardiovascular disease.
Our findings contribute to our understanding of interrelationships
among NOS, COX and ROS. Future studies are needed to
complete the picture of the cellular mechanisms of vascular
dysfunction and unveil novel therapeutic targets to improve
vascular health and reduce associated risks in obese individuals.
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